Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.

Quotes for Double Bond Pharmaceutical International AB

Right Now

+/-
0.002
%
0,36%
Latest
0.562
High
0.64
Low
0.54
Volume
290 995
Turnover (SEK)
162 662
Market Value (MSEK)
56,8
Time (Latest trade)
2024-04-23 14:47

Board

CEO

  • Igor Lokot

Chairperson of the Board

  • Sanna Rejnlander

Board

  • Igor Lokot
  • Irina Zaitseva
  • Sergey Yanitsky

Videos

Largest Owners

Name Capital % Votes % Date
Igor Lokot 9,46 16,80 2024-03-26
Per Ahlström 7,44 6,83 2024-03-26
KSDR Hamberg AB 7,21 6,63 2024-03-26
QQM Fund Management AB 6,11 5,62 2024-03-26
Carl Carvalho 4,26 3,92 2024-03-26
Investentia AB 3,90 3,58 2024-03-26
Lars-Åke Börje Flarke 3,65 3,36 2024-03-26
Avanza Pension 2,84 2,61 2024-03-26
Magnus Hamberg 2,40 2,21 2024-03-26
Obain AB 1,40 1,29 2024-03-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream